



Thursday, March 31, 2011

Australian Securities Exchange Announcement

Presbyterian Hospital / Columbia University Medical Center
announce the use of L-Dex testing for aiding in the clinical
assessment of unilateral lymphoedema of the arm

NOT FOR DISTRIBUTION OR RELEASE IN THE UNITED STATES OR TO U.S. PERSONS

Brisbane, Australia. – **ImpediMed Limited** (“**ImpediMed**” or the “**Company**”) refers to a recent announcement from the Presbyterian Hospital / Columbia University Medical Center in New York. Breast cancer specialists at the Presbyterian Hospital / Columbia University Medical Center are offering patients L-Dex testing to aid clinicians in their clinical assessment of breast cancer patients for unilateral lymphoedema of the arm.

The relevance of this media release to the Company and our shareholders is that this prestigious and globally recognised institute identifies the importance of BIS technology (L-Dex) and its role in measuring the extracellular fluid differences of the arms of female breast cancer patients to aid in the clinical assessment of lymphoedema. Within the well published pathophysiology of lymphoedema, extracellular fluid is recognized as an early clinical change in the development of this disorder.

As our shareholders are aware, ImpediMed’s U400 has a CE Mark and is a TGA listed device for sale in the European and Australian markets as an aid in the diagnosis of early lymphoedema. In the US market, ImpediMed’s U400 is cleared as - “A bioelectrical impedance analyser/monitor utilizing impedance ratios that supports the measurement of extra cellular fluid volume differences between the arms to aid in the clinical assessment of secondary unilateral lymphoedema in female breast cancer patients.”

Please find the link to the Presbyterian Hospital / Columbia University Medical Center media release below – reference to BIS testing.

<http://nyp.org/news/hospital/breast-cancer-technology.html>

Enquiries directed to ImpediMed’s CEO, Greg Brown, on +61 7 3860 3700.

ENDS

NOT FOR DISTRIBUTION OR RELEASE IN THE UNITED STATES

This announcement has been prepared for publication in Australia and New Zealand and may not be distributed or released in the United States. This announcement does not constitute promotion for the use of BIS devices in the United States or in any other jurisdiction in which such device clearance has not been obtained. **This device is not intended to diagnose or predict lymphoedema of an extremity.**

5735201/1In Australia:
ImpediMed Limited
Unit 1, 50 Parker Court
Pinkenba, QLD 4008
Phone : +61-7-3860-3700

ASX CODE: IPD

For personal use only